Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma [ID1305]
Discontinued
Reference number: GID-TA10244
As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of pembrolizumab for gastric or gastroesophageal junction adenocarcinoma.
Please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early November 2018.